Rigel Pharmaceuticals, Inc. (RIGL)
NASDAQ: RIGL · Real-Time Price · USD
19.27
+0.21 (1.08%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Rigel Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Rigel Pharmaceuticals stock have an average target of 36.8, with a low estimate of 23 and a high estimate of 57. The average target predicts an increase of 91.02% from the current stock price of 19.27.
Analyst Consensus: Buy
* Price targets were last updated on Mar 6, 2025.
Analyst Ratings
The average analyst rating for Rigel Pharmaceuticals stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $49 → $55 | Strong Buy | Maintains | $49 → $55 | +185.49% | Mar 6, 2025 |
| B. Riley Securities | B. Riley Securities | Hold Maintains $20 → $24 | Hold | Maintains | $20 → $24 | +24.58% | Mar 5, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $57 | Strong Buy | Reiterates | $57 | +195.87% | Mar 5, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $57 | Strong Buy | Reiterates | $57 | +195.87% | Jan 23, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $57 | Strong Buy | Reiterates | $57 | +195.87% | Jan 14, 2025 |
Financial Forecast
Revenue This Year
201.74M
from 179.28M
Increased by 12.53%
Revenue Next Year
233.37M
from 201.74M
Increased by 15.68%
EPS This Year
1.06
from 0.99
Increased by 7.07%
EPS Next Year
1.76
from 1.06
Increased by 66.44%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 215.6M | 250.7M | 294.0M | ||
| Avg | 201.7M | 233.4M | 266.7M | ||
| Low | 185.0M | 211.4M | 242.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 20.2% | 24.3% | 26.0% | ||
| Avg | 12.5% | 15.7% | 14.3% | ||
| Low | 3.2% | 4.8% | 3.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.39 | 3.45 | 6.03 | ||
| Avg | 1.06 | 1.76 | 3.51 | ||
| Low | 0.69 | 0.66 | 1.13 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 40.0% | 225.8% | 241.7% | ||
| Avg | 7.1% | 66.4% | 99.2% | ||
| Low | -30.7% | -38.1% | -36.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.